Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBT (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBT for 16 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 90.36% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.8 million, a 48.37% decrease, with the full-year FY2024 number at $76.4 million, down 25.48% from a year prior.
  • EBT was $1.8 million for Q3 2025 at Usana Health Sciences, down from $18.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $54.3 million in Q3 2021 to a low of $1.8 million in Q3 2025.
  • A 5-year average of $26.9 million and a median of $26.6 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: surged 35.85% in 2021, then tumbled 90.36% in 2025.
  • Usana Health Sciences' EBT stood at $40.4 million in 2021, then tumbled by 43.49% to $22.8 million in 2022, then increased by 16.7% to $26.6 million in 2023, then plummeted by 60.81% to $10.4 million in 2024, then plummeted by 82.8% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's EBT are $1.8 million (Q3 2025), $18.8 million (Q2 2025), and $16.7 million (Q1 2025).